Status: Recruiting
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
Participants needed: 56
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Implicit BioscienceUpdated: Aug 20, 2025Locations: 2
Eligibility criteria
Adult patients (18+) on mechanical ventilations with acute respiratory distress... [+6]
Significant pre-existing organ dysfunction prior to hospitalization [+23]